HER2+ breast cancer: concurrent trastuzumab + anthracyclines found safe

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Concurrent administration of trastuzumab and anthracyclines is no more cardiotoxic than sequential administration to patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer.
  • No difference in DFS or OS was reported between groups.

Why this matters

  • Concurrent administration is safe but should be tested in a larger randomized controlled trial (RCT).

Study design

  • In this RCT, patients with HER2+ breast cancer were randomly assigned to concurrent (n=101) or sequential (n=100) administration of trastuzumab (maintenance dose of 6 mg/kg) and anthracyclines (doses at the discretion of physician but cannot exceed 360 mg/m2 doxorubicin and 600 mg/m2 epirubicin).
  • Primary outcome was cardiotoxicity assessed by symptoms, ECG abnormalities, and left ventricular ejection fraction (LVEF) reduction.
  • Median follow-up was 42 months.
  • Funding: Beijing Natural Science Foundation; Beijing Municipal Science and Technology Key Development Program.

Key results

  • No difference was found in cardiotoxicity, with 19.4% meeting criteria for cardiac events in the concurrent group and 22.4% meeting criteria in the sequential group (P=.598).
  • No difference was found in mean LVEF between the 2 groups at 3, 6, 9, 12, and 24 months after the first dose of trastuzumab.
  • Groups showed similar DFS (P=.901) and OS (P=.495).

Limitations

  • Few patients for survival analysis.